Collste P, Seideman P, Borg K O, Haglund K, von Bahr C
Clin Pharmacol Ther. 1979 Apr;25(4):423-7. doi: 10.1002/cpt1979254423.
Six healthy subjects were given placebo and a single oral 0.2-gm dose of alprenolol (Aptin) before and after 0.1 gm pentobarbital at bedtime for 10 days. The plasma concentrations of alprenolol and its metabolite 4-hydroxy-alprenolol and the inhibition of exercise tachycardia were studied for 7 hr after the alprenolol. Alprenolol and 4-hydroxy-alprenolol plasma levels were decreased by about 40% by pentobarbital but plasma half-lives were unchanged. The inhibition of exercise tachycardia during a 7-hr period was reduced from 14.0% to 10.7% by pentobarbital. The reduction was proportional to the decreased drug plasma levels. There was a significant contribution of the metabolite to alprenolol effect. The estimation of relative potency of metabolite against parent compound was 0.9 before pentobarbital and 1.9 after pentobarbital.
六名健康受试者在睡前服用0.1克戊巴比妥10天前后,分别给予安慰剂和单次口服0.2克阿普洛尔(心得舒)。在服用阿普洛尔后7小时,研究了阿普洛尔及其代谢物4-羟基阿普洛尔的血浆浓度以及运动性心动过速的抑制情况。戊巴比妥使阿普洛尔和4-羟基阿普洛尔的血浆水平降低了约40%,但血浆半衰期未变。戊巴比妥使7小时内运动性心动过速的抑制率从14.0%降至10.7%。这种降低与药物血浆水平的下降成正比。代谢物对阿普洛尔的作用有显著贡献。戊巴比妥前代谢物相对于母体化合物的相对效价估计为0.9,戊巴比妥后为1.9。